The effects of the Covid-19 virus, which swept the world, still continue. It is necessary to be very careful and conscious in order to be protected from the effects of Covid-19, which causes the death of millions of people and changes in their health. Citizens are experiencing various concerns due to the increasing Covid-19 cases. Recently, BA.4 and BA.5 Omicron variants cause this virus to spread rapidly. According to the news in the Financial Times, the expected statement came from BioNTech, owned by Özlem Türeci and Uğur Şahin.
THE VACCINE IS INTENDED TO BE DISTRIBUTED IN OCTOBER
BioNTech and Pfizer will begin a clinical trial of a Covid-19 vaccine adapted to Omicron’s BA.4 and BA.5 variants this month, as German biotech predicts a surge in demand at the end of the year. BioNTech has been producing doses of the first Omicron vaccine targeting the BA.1 variant since spring and is ready for delivery when approved by a regulator. The company aims to distribute the vaccine, which will be potent against variants BA.4 and BA.5, in early October, if it receives regulatory approval.
MORE POWERFUL THAN OTHER VARIANTS
Chief medical officer Özlem Türeci said that data from studies in mice (previously predictive) showed that shot targeting BA.4 and BA.5 elicited a stronger immune response against these variants and all other sub-variants of Omicron. told. He said this data, combined with his extensive experience and data from previous Covid vaccines, could be sufficient for emergency approval and provide “timely response”.
WHAT ARE THE SYMPTOMS OF BA.4 AND BA.5 VARIANTS?
Symptoms of the new variants are listed as follows:
- High fever, cough and shortness of breath
- Fatigue and weakness
- Body, head and sore throat
- Nasal congestion or runny nose
- Loss of appetite and diarrhea
- Rare loss of taste and smell